Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 167.70 INR
Change Today -2.00 / -1.18%
Volume 31.8K
VNR On Other Exchanges
Natl India
As of 12:14 AM 05/7/15 All times are local (Market data is delayed by at least 15 minutes).

venus remedies ltd (VNR) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/15/14 - 381.75
52 Week Low
03/23/15 - 95.60
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for VENUS REMEDIES LTD (VNR)

Related News

No related news articles were found.

venus remedies ltd (VNR) Related Businessweek News

No Related Businessweek News Found

venus remedies ltd (VNR) Details

Venus Remedies Limited manufactures and trades in medicines in India and internationally. The company primarily offers fixed dosage injectable products. Its product portfolio includes approximately 75 products in various therapeutic segments comprising oncology, anti-infective, neurology, cardiology, orthopedic, pain management, pediatrics, and surgery. The company offers its products under the Mebatic, Calridol, Moximicin, Neurotol, Glutapep, Doxol, Paxol, Citabol, Epirol, Ronem, Immunox, Pimcef, Fejet IV, Parin-E, Vanconex, Dobutacard, Sulbactomax, Supime, Tobracef, Pirotum, Texedol, Potentox, Elores, Achnil, Vancoplus, and other brand names. Venus Remedies Limited was incorporated in 1989 and is headquartered in Panchkula, India.

Founded in 1989

venus remedies ltd (VNR) Top Compensated Officers

Chairman of the Board, Chief Executive Office...
Total Annual Compensation: 6.1M
Joint Managing Director, Head of Venus Medici...
Total Annual Compensation: 5.3M
Whole Time Director and Chief Executive Offic...
Total Annual Compensation: 2.9M
Executive Director of Marketing, Executive Di...
Total Annual Compensation: 3.2M
Compensation as of Fiscal Year 2014.

venus remedies ltd (VNR) Key Developments

Venus Remedies Ltd., Board Meeting, Feb 13, 2015

Venus Remedies Ltd., Board Meeting, Feb 13, 2015. Agenda: To consider quarterly results.

Venus Remedies Ltd. to Report Q3, 2015 Results on Feb 13, 2015

Venus Remedies Ltd. announced that they will report Q3, 2015 results on Feb 13, 2015

Venus Remedies Ltd., Annual General Meeting, Dec 30, 2014

Venus Remedies Ltd., Annual General Meeting, Dec 30, 2014., at 10:00 Indian Standard Time. Agenda: To consider and adopt the balance sheet, as on March 31, 2014 and profit and loss account for the year ended March 31, 2014 along with report of directors and auditor's report thereon; to consider the reappointment of statutory auditors; to approve the remuneration of cost auditors; and to consider the appointment and reappointment of directors.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VNR:IN 167.70 INR -2.00

VNR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VNR.
View Industry Companies

Industry Analysis


Industry Average

Valuation VNR Industry Range
Price/Earnings 2.1x
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow 1.3x
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VENUS REMEDIES LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at